Ublituximab: Phase Ib final data

Final data from 11 evaluable patients with relapsed CLL who received >=1 prior therapy with fludarabine in an open-label, French Phase Ib trial showed that ublituximab led to 5 partial responses at 6 months, all of which were maintained at 12 months of follow-up. Median PFS was not reached at 12 months. The most common treatment-related adverse event reported was infusion-related reactions. TG Therapeutics said the toxicity profile was consistent with anti-CD20-directed therapies. Patients received ublituximab once weekly for 8 weeks, with an initial 150 mg infusion in the first week followed by 7 weekly doses of 450 mg. Data were presented at the European Hematology Association meeting in Stockholm. ...